Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CAE expands healthcare simulation offering with METI buy

This article was originally published in Clinica

Executive Summary

Canadian firm CAE Healthcare, part of civil aviation and defence simulation and training specialist CAE, has acquired Medical Education Technologies Inc (METI), a developer of medical simulation technology, for $130m. The deal will make CAE a leader in the healthcare simulation segment, and expand its global footprint and product offering. As well as its headquarters in Sarasota, Florida, METI has facilities in Hungary and Germany. It reports revenues of over $60m per year. The company's CEO Michael Bernstein will take on the role of president of the merged CAE Healthcare. CAE expects the deal to boost its core market segment, which includes healthcare and mining. It predicts the unit will achieve revenues of $120m and be profitable by fiscal 2013. CAE has issued $150m of senior notes in a private placement to fund the acquisition.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel